CD36 and prostate cancer: The established HA@CD36i‐TR@siSCD1 nanosystem actively targets prostate cancer (PCa) and is multiresponsive to release cluster of differentiation 36 (CD36) inhibitor in tumor microenvironment and release stearoyl‐CoA desaturase 1 (SCD1) siRNA in tumor cell, respectively, to regulate lipid uptake and synthesis of PCa.